Physician profile
John A Cockerell
NPI 1669867099
$8,981.94
in general payments reported to CMS, 2019-2025
41 companies · $345 in 2025
The $345 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,034 · 2020: $1,084 · 2021: $1,467 · 2022: $1,729 · 2023: $1,636 · 2024: $1,689 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,669.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,132.33 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $875.10 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $815.18 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $738.57 | 2021-2025 | Vraylar, Qulipta, Viberzi |
| Lilly USA, LLC | $717.20 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $656.72 | 2019-2024 | Otezla, Repatha |
| Abbott Laboratories | $459.77 | 2022-2025 | Freestyle Libre 3 |
| Pfizer INC. | $445.57 | 2019-2024 | |
| Astellas Pharma US INC | $428.11 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $299.70 | 2019-2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $285.81 | 2019-2024 | Jardiance, Synjardy |
| Antares Pharma, INC. | $226.16 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Biohaven Pharmaceutical Holding Company LTD. | $208.55 | 2022 | |
| Amarin Pharma, INC. | $207.50 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $166.85 | 2020-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cockerell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.